ACN Newswire
Read More

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

indie
4 minutes

HONG KONG, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital. The proceeds from this round of financing will be used to accelerate the product R&D, market expansion, and data-driven precision medicine development and help APTBIO continue to develop in mass spectrometry multi-omics applications, innovative drug development, and preclinical research, making a forward-looking layout for the construction of precision medicine services driven by big data and AI. Founded in July 2004, APTBIO is one of the earliest biotechnology companies engaged in proteomics technical services and biopharmaceutical research and analysis services in China and participated in establishing China's biological mass spectrometry applications from scratch. With headquarter in Shanghai, APTBIO has a nationwide sales network and it has built innovative technology centers, data centers, and clinical testing centers in Shanghai, Yiwu, and Taiz...

SeaPRwire

Researchers identify possible predictor of early heart disease in the elderly: NHCS

aseanpr
3 minutes

SINGAPORE - Researchers here have found a potential predictor of heart disease among the elderly, after discovering a link between the weakening of skeletal muscle function and heart size. The skeletal muscle is attached to bones around the body and helps with muscle movement. The age-related loss of skeletal muscle mass and function is known as sarcopenia, and it affects 10 per cent of older healthy adults. While such skeletal muscle degeneration is known, the impact of sarcopenia on the ageing heart had not been identified. This was what the study led by the National Heart Centre Singapore (NHCS) sought to address. The longitudinal study, known as the Cardiac Ageing Study, began in 2014 and involved more than 300 healthy adults between 40 and 80 years old. It aimed to study the characteristics of how the heart ages - in both structure and function - within the local population. Based on detailed scans and various assessments such as skeletal muscle mass measurements and hand grip strength tests, the researchers found significant associations between skeletal muscle mass, function and heart structure. Over 20 per cent of older adults with sarcopenia had a distinct pattern of struc...

ACN Newswire

兆科眼科(6622.HK)两项产品通过国家药监局药品注册现场核查及GMP符合性检查

tallulah
1 minute

HONG KONG, May 24, 2021 - (亚太商讯 via SEAPRWire.com) - 致力于眼科疗法的研究、开发及商业化的眼科制药公司——兆科眼科有限公司(「兆科眼科」或「公司」；股份代号：6622)，宣布两项药品——贝美素噻吗洛尔滴眼液(在中国用于治疗青光眼的潜在首仿药，为前列腺素类似物与乙型受体阻断剂的固定剂量复方)；及盐酸依匹斯汀滴眼液(在中国用于治疗过敏性结膜炎的潜在首仿药，具有抗组胺及稳定的肥大细胞双重作用机制)，通过国家药品监督管理局药品审评检查大湾区分中心药品注册现场核查，核实上述两项药品的研制过程及生产过程中的原始记录及数据。公司亦通过广东省药监局同步进行的药品生产质量管理规范(GMP)符合性检查，确认本公司制定了GMP管理框架、核心团队人员及整套分析仪器、设备和设施、管理完善的文件体系以及正常运作的生产与质量体系。通过药品注册现场核查及GMP符合性是本公司重大里程碑。作为国家药品监督管理局药品审评检查大湾区分中心首个注册核查的企业，是次正面检查结果象征国家药监局对本公司的药物研发体系实力及质量管理体系的认可，证明体系能确保持续稳定地生产出符合注册要求的药品。公司于广州市南沙新区的生产设施占地约7,600平方米，根据中国、美国及欧盟cGMP标准设计及兴建以用于生产眼科药物，其生产能力完备并可用于商业化规模生产。公司正在扩充其生产能力，预期于2022年底前完成扩建。兆科眼科董事会主席、执行董事兼行政总裁李小羿博士表示：「眼睛是人体一个非常敏感的器官，因此我们非常重视生产质量及安全性，致力为病人提供最安全及优质的产品。优质制造是兆科的核心支柱之一，通过国家药品监督管理局药品注册现场核查乃本公司的重要认证，肯定我们多年来为落实优质生产体系所作的一切努力。」兆科眼科已向国家药监局提交了以上所阐述之两种仿制药(贝美素噻吗洛尔滴眼液及盐酸依匹斯汀滴眼液)的简化新药申请。本公司预期在2022年获得监管批准后开始将该等两个产品商业化，及预期有关商业化能迎合青光眼病人尚未满足的需求，并有助本公司与合作伙伴及关键意见领袖、眼科医生及医院等战略渠道建立紧密下游联系。关于兆科眼科有限公司兆科眼科有限公司是一家致力于眼科疗法的研究、开发及商业化，以满足中国国内巨大医疗需求缺口的眼科制药公司。通过自主开发或许可引进，公司已建立起包含25种候选药物的全面眼科药物管线，由13种创新药物及12种仿制药组成，涵盖影响眼前节及眼后节的多数主要眼科适应症。此外，公司已在眼科药物开发主要方面培养出内部能力。专门的内部研发、临床及监管能力令公司能够同步推进多种创新及仿制候选药物通过临床前及临床阶段。为准备近期的产品推出，公司已根据中国、美国及欧盟cGMP标准设计及兴建一座具商业规模的先进生产设施用于生产眼科药物。公司由一支在研发、临床运营、制造、监管沟通、业务发展及...

JCN Newswire
Read More

Fujitsu and Hokkaido University Develop “Explainable AI” Technology Providing Users with Concrete Steps to Achieve Desired Outcomes

ruth
9 minutes

KAWASAKI, Japan, Feb 4, 2021 - (JCN Newswire) - Fujitsu Laboratories Ltd. and Hokkaido University today announced the development of a new technology based on the principle of "explainable AI" that automatically presents users with steps needed to achieve a desired outcome based on AI results about data, for example, from medical checkups."Explainable AI" represents an area of increasing interest in the field of artificial intelligence and machine learning. While AI technologies can automatically make decisions from data, "explainable AI" also provides individual reasons for these decisions - this helps avoid the so-called "black box" phenomenon, in which AI reaches conclusions through unclear and potentially problematic means.While certain techniques can also provide hypothetical improvements one could take when an undesirable outcome occurs for individual items, these do not provide any concrete steps to improve.For example, if an AI that makes judgments about the subject's health status determines that a person is unhealthy, the new technology can be applied to first explain the reason for the outcome from health examination data like height, weight, and blood pressure. Then, th...